Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
Real-world evidence on the impact of monoclonal antibodies as first-line treatment in Spain is limited. This observational, retrospective and prospective, multicenter, descriptive study included 117 transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients divided into Group A, who...
Saved in:
Main Authors: | Felipe de Arriba de la Fuente (Author), Mercedes Gironella Mesa (Author), Miguel Teodoro Hernández García (Author), Juan Alonso Soler Campos (Author), Susana Herráez Rodríguez (Author), María José Moreno Belmonte (Author), Teresa Regueiro López (Author), Miriam González-Pardo (Author), María Casanova Espinosa (Author), on behalf of the CARINAE Study Investigators (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2020) -
First person - Carina Lund
Published: (2020) -
Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
by: Vukićević Đurđa, et al.
Published: (2020) -
CAMPUR KODE PADA ALBUM DON’T STOP OLEH AI CARINA UEMURA
by: Anni Asokawati, et al.
Published: (2015) -
Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy
by: Shao IH, et al.
Published: (2014)